Skip to Main Content

Should Enthusiasm Surrounding Antibiotics Be Tempered?

White Paper|

By Chris Apolito, Partner; Kate Kitsopoulos, Principal; Ryan Coe, Strategy Consultant; Megan Thomas, Strategy Analyst

The market for antibiotics has gained considerable attention over the past few years with an increasing number of development programs and an upturn in the number and value of antibiotic-driven deals. However, this activity may be viewed as overly optimistic as significant challenges for new antibiotic programs still persist—limited diagnostic adoption and an unfavorable reimbursement landscape.

Should Enthusiasm Surrounding Antibiotics Be Tempered?

Please submit the form below to view this resource.

Request Access

Please fill out the form below to access our Industry Resources.

By submitting this form, you agree to our use of this information for the purpose of contacting you. For more information, please refer to our privacy policy.

Maximize value across the product and patient journeys. Find out how.